surmount-1 tirzepatide trial obesity without diabetes weight loss percentage surmount trials 72 weeks Tirzepatide cuts risk by 94% in Semaglutide vs tirzepatide vs retatrutide: – 🤔Adults with type 2 diabetes

Fatima Cody Stanford, M.D., an obesity medicine physician at Massachusetts General Hospital and associate professor at Harvard Medical School

Analysis is ongoing to compare differences in weight loss, lean mass, and fat mass reduction between those using tirzepatide and those using semaglutide

For lyophilized powder, moisture exposure before reconstitution is the enemy

We're moving away from viewing obesity as a number on the scale and toward treating it as a complex chronic metabolic disease that influences diabetes, fatty liver disease, cardiovascular health, sleep apnea, kidney disease, and quality of life

You might see plateau periods or modest gains during high-dose steroid phases, even on tirzepatide